NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

November 30, 2016

Conditions
Prostatic NeoplasmsProstate Cancer
Interventions
DRUG

TAK-700

TAK-700 will be administered at 300mg twice per day on 28-day continuous cycles

RADIATION

Fluorine F 18 Sodium Fluoride

Undergo NaF F18 PET/CT scan

PROCEDURE

Positron Emission Tomography

Undergo 18F NaF PET/CT scan

PROCEDURE

Computed Tomography

Undergo 18F NaF PET/CT scan

Trial Locations (1)

53792

University of Wisconsin Carbone Cancer Center, Madison

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

University of Wisconsin, Madison

OTHER